| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/04/2003 | EP0665752B1 Pharmaceutical compositions containing 3-beta-hydroxylated natural steroid derivatives, and use thereof |
| 06/04/2003 | EP0656007B1 Delta opioid receptor genes |
| 06/04/2003 | CN1422281A G-protein coupled receptors |
| 06/04/2003 | CN1422121A Protein stabilised emulsions |
| 06/04/2003 | CN1421460A Conjugate of lidamycin, monoclonal antibody and its Fab'segment and its application in targeting treatment of colon cancer and other tumors |
| 06/04/2003 | CN1421459A Humanized CD3-resisting monoclonal antibody |
| 06/04/2003 | CN1110557C LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idio type antibody |
| 06/04/2003 | CN1110556C Isolated nucleic acid molecules for coding tumor rejection antigen precursor MAGE-3 and use thereof |
| 06/04/2003 | CN1110553C Gene engineering adenovirus and it application |
| 06/04/2003 | CN1110323C Rotavirus resisting immune globulin composition and its producing process and use |
| 06/04/2003 | CN1110322C Monoclonal antibody Fab'-pingyangmycin conjugate and its anticancer action |
| 06/03/2003 | US6573368 Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| 06/03/2003 | US6573364 Isolation and characterization of Hermansky Pudlak Syndrome (HPS) protein complexes and HPS protein-interacting proteins |
| 06/03/2003 | US6573245 Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof |
| 06/03/2003 | US6573242 Composition for activating macrophages comprising S-(2,3-dihydroxypropyl)-cysteine peptide having two fatty acids bonded as esters to dihydroxypropyl group and having specified amino acid sequence |
| 06/03/2003 | US6573236 Myelin oligodendrocyte glycoprotein (MOG) polypeptide-specific antibody to bind a natural MOG polypeptide and competitively inhibit the binding of an autoantibody, does not comprise functional Fc portion; multiple sclerosis |
| 06/03/2003 | US6573096 Continuous cell lines which produce monospecific antibodies that specifically bind an epitope of a human dipeptidyl peptidase IV and thereby inhibit angiogenesis; use in treatment of cancer |
| 06/03/2003 | US6573093 Temperature sensitive plasmids of P. haemolytica |
| 06/03/2003 | US6573090 Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| 06/03/2003 | US6573082 Streptococcus pneumoniae antigens and vaccines |
| 06/03/2003 | US6573081 Method for growing circoviruses |
| 06/03/2003 | US6573079 Methods and interferon deficient substrates for the propagation of viruses |
| 06/03/2003 | US6573066 FtsH from Staphylococcus aureus |
| 06/03/2003 | US6573064 Method of screening anti-mycobacterial molecules |
| 06/03/2003 | US6573003 Soluble recombinant fusion protein comprising a nontoxin protein sequence and portion of Clostridium difficile toxin B amino acid sequence 10; pseudomembranous enterocolitis; side effect free; low cost |
| 06/03/2003 | US6572867 Reducing plasma levels of anti-( alpha Gal(1,3)Gal) antibodies; nonimmunogenic polymers comprise alpha Gal(1,3) Gal moieties covalently linked to said polymer; cross-links are covalent tethers, derived from N-hydroxysulfosuccinimide |
| 06/03/2003 | US6572866 Nerve growth factor as a vaccine adjuvant |
| 06/03/2003 | US6572865 Mycobacterium tuberculosis DNA sequences encoding immunostimulatory peptides and methods for using same |
| 06/03/2003 | US6572864 Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
| 06/03/2003 | US6572863 Genome is modified to disable VPR and TAT to prevent their expression; stop codons to prevent translation |
| 06/03/2003 | US6572861 Lecithin, oil in water emulsion and an amphiphilic surfactant; minimize local reactions to the vaccine |
| 06/03/2003 | US6572860 ICP27, glycoprotein B, ribonucleotide reductase, ICP4, ICP34.5, glycoprotein E or glycoprotein F and an immunomodulatory peptide which is a portion of an immunoprotein which promotes binding to a class of T cells and |
| 06/03/2003 | US6572859 Hypoallergenic polypeptide consisting of an amino acid sequence of SEQ ID NO: 20 and 21; Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity |
| 06/03/2003 | US6572857 Psoriasis; humanized sub clone of IOR T1A produced by the hybridoma deposited with ECACC, CAMR under accession number 96112640, having heavy and light chains with humanized variable regions. |
| 06/03/2003 | US6572856 Classic complement pathway, C3 convertase |
| 06/03/2003 | US6572852 Genetic engineering |
| 06/03/2003 | CA2138997C Vaccine composition containing adjuvants |
| 06/03/2003 | CA2108266C Convertible microemulsion formulations |
| 06/03/2003 | CA2101639C Herpes simplex virus-1 deletion variants and vaccines thereof |
| 05/30/2003 | WO2003044184A1 Treatment of pml targeting jc virus agno |
| 05/30/2003 | WO2003044183A1 Interleukin-2 gene transferred lymphokine activated killer cells |
| 05/30/2003 | WO2003044172A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 05/30/2003 | WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 05/30/2003 | WO2003044162A2 Genes encoding g-protein coupled receptors and methods of use therefor |
| 05/30/2003 | WO2003044054A2 Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases |
| 05/30/2003 | WO2003044048A2 Methylated heparin-binding hemagglutinin (hbha) recombinant mycobacterial antigen |
| 05/30/2003 | WO2003044047A2 Virulence proteins of the genus yersinia and uses thereof |
| 05/30/2003 | WO2003044036A1 Tumor specific monoclonal antibodies |
| 05/30/2003 | WO2003043986A1 Polypeptides of moraxella (branhamella) catarrhalis |
| 05/30/2003 | WO2003043654A1 Recombinant vaccinia virus vaccine |
| 05/30/2003 | WO2003043649A1 Removal promoters and inhibitor for apoptosis cells in vivo |
| 05/30/2003 | WO2003043587A2 Recovery of recombinant human parainfluenza virus type 1 (hpiv1) from cdna |
| 05/30/2003 | WO2003043583A2 Treatment of immunological disorders using anti-cd30 antibodies |
| 05/30/2003 | WO2003043574A2 Pharmaceutical compositions in particulate form |
| 05/30/2003 | WO2003027248A3 Antibody inhibitors of gdf-8 and uses thereof |
| 05/30/2003 | WO2003026691A3 Use of hmgb1 for the activation of dendritic cells |
| 05/30/2003 | WO2003016917A3 Sodium channel regulators and modulators |
| 05/30/2003 | WO2003015817A3 Oral immunoglobulin treatment for inflammatory bowel disease |
| 05/30/2003 | WO2003008448A3 Novel human proton-gated channels |
| 05/30/2003 | WO2003006055A3 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 05/30/2003 | WO2003005952A3 Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres |
| 05/30/2003 | WO2003004650A3 Group b streptococcus antigens and corresponding dna fragments |
| 05/30/2003 | WO2003001204A3 Type 1 diabetes diagnostics and therapeutics |
| 05/30/2003 | WO2002102853A3 Cd4-specific antibody trx1 and uses therefor |
| 05/30/2003 | WO2002100328A3 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels |
| 05/30/2003 | WO2002098891A3 GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 05/30/2003 | WO2002092132A3 Microparticles and methods for delivery of recombinant viral vaccines |
| 05/30/2003 | WO2002078698A3 Polarisation of dendritic cells (treatment of infections, cancer and autoimmune diseases) using histamine |
| 05/30/2003 | WO2002077029A3 Cd19-specific redirected immune cells |
| 05/30/2003 | WO2002076501A3 Blood cell production via activation of the hemoglobin scavenger receptor |
| 05/30/2003 | WO2002076499A3 Combination treatment of pancreatic cancer |
| 05/30/2003 | WO2002076485A3 Vaccine for modulating between t1 and t2 immune responses |
| 05/30/2003 | WO2002068632A3 Methods to identify mutant cells with altered sialic acid |
| 05/30/2003 | WO2002064621A3 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
| 05/30/2003 | WO2002057314A3 Prevention and treatment of hcv infection employing antibodies directed against conformational epitopes |
| 05/30/2003 | WO2002036160A3 Method for obtaining antigenic structures enhancing specific cross reactivity |
| 05/30/2003 | WO2002034291A3 Compositions and methods for treating hematologic malignancies and multiple drug resistance |
| 05/30/2003 | WO2002031025A9 Biodegradable poly(beta-amino esters) and uses thereof |
| 05/30/2003 | WO2002000692A9 Pd-l2 molecules: pd-1 ligands and uses therefor |
| 05/30/2003 | WO2001096381A3 IMMUNIZATION OF DAIRY CATTLE WITH GapC PROTEIN AGAINST STREPTOCOCCUS INFECTION |
| 05/30/2003 | WO2001091792A3 Anti-adhesion molecule antibody to treat inflammation and cancer by inducing the idiotypic network |
| 05/30/2003 | WO2001052874A9 Intra-tumoral administration of il-12 encoding nucleic acid molecules |
| 05/30/2003 | CA2467958A1 Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna |
| 05/30/2003 | CA2467930A1 Treatment of pml targeting jc virus agno |
| 05/30/2003 | CA2467908A1 Mfg-e8-l regulates phagocytic removal of apoptotic cells by macrophages |
| 05/30/2003 | CA2467242A1 Treatment of immunological disorders using anti-cd30 antibodies |
| 05/30/2003 | CA2467206A1 Genes encoding g-protein coupled receptors and methods of use therefor |
| 05/30/2003 | CA2467020A1 Tumor specific monoclonal antibodies |
| 05/30/2003 | CA2466982A1 Pharmaceutical compositions in particulate form |
| 05/30/2003 | CA2466937A1 Methylated heparin-binding hemagglutinin (hbha) recombinant mycobacterial antigen |
| 05/30/2003 | CA2464957A1 Polypeptides of moraxella (branhamella) catarrhalis |
| 05/30/2003 | CA2464542A1 Composition comprising and method of using angiopoietin-like protein 3 angptl3 |
| 05/30/2003 | CA2463790A1 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 05/29/2003 | US20030100706 Nucleotide sequences coding polypeptide for use in the prevention and treatment of bacterial infections |
| 05/29/2003 | US20030100588 Indole-type inhibitors of p38 kinase |
| 05/29/2003 | US20030100570 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 05/29/2003 | US20030100567 Tyrosine kinase inhibitors |
| 05/29/2003 | US20030100527 Immunostimulatory nucleic acid molecules for activating dendritic cells |
| 05/29/2003 | US20030100525 Amino acid sequences; anticaner agents, monitoring, diagnosis |
| 05/29/2003 | US20030100520 Immunizing mammal with inoculum containing a vehicle in which is dissolved or dispersed recombinant DNA molecule; maintaining immunized mammal for a time period for production of antibodies that bind to cholesteryl ester transfer protein |